Overview
- 7 inspections across 7 sites are on record.
- 7 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-09-06.
At a glance
Inspections
7
Sites
7
Observations
7
Career since
Feb 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Cyrille Hulin, M.D. | 6 Sep 2019 | Human Drugs | |
| PPD, Inc., part of Thermo Fisher Scientific | 15 Aug 2019 | Human Drugs | View 483 → |
| Novartis Pharmaceuticals Corporation | 14 Dec 2018 | Human Drugs | View 483 → |
| Conrado Estol, M.D. | 12 Jan 2018 | Human Drugs | View 483 → |
| Chemo Research S.L.U. | 19 Jul 2017 | Human Drugs |
Sites inspected
Cyrille Hulin, M.D.Pessac Cedex, France1 insp.
PPD, Inc., part of Thermo Fisher ScientificMorrisville, United States1 insp.
Novartis Pharmaceuticals CorporationEast Hanover, United States1 insp.
Conrado Estol, M.D.Buenos Aires, Argentina1 insp.
Chemo Research S.L.U.Madrid, Spain1 insp.
Co-investigators
Investigators who share inspections with this person.
Cheryl A Grandinetti2 shared
Rebecca T Davis1 shared
Eileen J Bannerman1 shared
Sheri S Oliver1 shared
Peter R Lenahan1 shared
Tracy R Ball1 shared
Gene R Gunn1 shared
Ethan P Stegman1 shared
Tara K Carmody1 shared
Full investigator report
Get the verbatim findings behind Kassa Ayalew's 7 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site